Pharmacological study of possible protective effects of nano-coenzyme Q10 and nano-selenium against simvastatin-induced myopathy in hyperlipidemic rats / (Titelsatznr. 59453)
[ MARC ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06280nam a22002537a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 180912s2017 ua a|||g bm|| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | SOUL |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Edition number | 21 |
| Classification number | 615 |
| Item number | A P |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 4927 |
| Personal name | Abo-Zalam, Hagar Belal Ahmad. |
| 245 10 - TITLE STATEMENT | |
| Title | Pharmacological study of possible protective effects of nano-coenzyme Q10 and nano-selenium against simvastatin-induced myopathy in hyperlipidemic rats / |
| Statement of responsibility, etc. | Hagar Belal Ahmad Abo-zalam ; Supervised By Rania E. Abdalsala, Mahmoud M. Khattab, Mohamed A. Hamzawy. |
| 246 01 - VARYING FORM OF TITLE | |
| Title proper/short title | دراسة فارماكولوجية للتأثيرات الوقائية المحتملة لكل من نانوكوانزيم كيو 10 ونانو السيلينيوم ضد الاعتلال العضلي المحدث بدواء سيمفاستاتين في فرط الدهون المحدث تجريبيا في الجرذان |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc. | Cairo : |
| Name of publisher, distributor, etc. | Cairo University, |
| Date of publication, distribution, etc. | 2017. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | xxv, 6, 246 p. : |
| Other physical details | ill. ; |
| Dimensions | 26 cm. |
| Accompanying material | +CD. |
| 500 ## - GENERAL NOTE | |
| General note | Thesis (M.Sc.) – Cairo University. Faculty of Pharmacy. Department of Pharmacology & Toxicology. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc | Includes bibliographical references. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Introduction: Statins are the drug of choice for treatment of hyperlipidemia and prevention of cardiovascular diseases. Treatment with statins dropped off due to adverse effects as hepatotoxicity and myopathy. The purpose of the current study is to make comparison between simvastatin (20 mg/kg) and nano-simvastatin at doses 20mg/kg and 5 mg/kg and to elucidate the synergistic effect of combination of simvastatin (SV), nano-coenzymeQ10 and/or nano-selenium in improving the therapeutic effect and reducing possible side effects. Methods: this study was divided in to two parts; each group contains (8-10) adult albino rats. First part composed of 5 groups; group 1: rats were received nano-vehicle, group 2: hyperlipidemic rats were introduced to high fat diet (HFD), group 3: hyperlipidemic rats treated by simvastatin (20mg/kg) (HFD & SV), group 4: hyperlipidemic rats treated by nano-simvastatin (20 mg/kg) (HFD & SVNPs20), group 5: hyperlipidemic rats treated by nano-simvastatin (5 mg/kg) (HFD & SVNPs5), Second part composed of 6 groups; group 1: nano-vehicle control group, group 2: hyperlipidemic rats were introduced to high fat diet (HFD), group 3: hyperlipidemic rats treated by simvastatin (20mg/kg) (HFD & SV), group 4: hyperlipidemic rats treated by simvastatin (20 mg/kg) and nano-coQ10 (10 mg/kg) (HFD &SV & coQNPs), group 5: hyperlipidemic rats treated by simvastatin (20 mg/kg) and nano-selenium (0.1 mg/kg) (HFD & SV & SeNPs), group 6: hyperlipidemic rats treated by simvastatin (20 mg/kg), nano-coQ10 (10 mg/kg) and nano-selenium (0.1 mg/kg) (HFD & SV & coQNPs & SeNPs). Hyperlipidemia was induced by feeding rats with high fat diet (HFD) for 16 weeks. Treatments were given orally starting from 13th week simultaneously with HFD for 30 days. Serum samples were separated for determination of lipid profile biomarkers [total cholesterol (T.C) - triglycerides (T.G) - high density lipoprotein (HDL) - low density lipoprotein (LDL) - atherogenic index (AIX)], glucose, insulin, liver function biomarkers [alanine aminotransferase (ALT) - aspartate aminotransferase (AST) – albumin - alkaline phosphatase (ALP)], biomarkers of muscle function [creatine kinase (CK) - myoglobin (MYO) - troponin (Tn-T)] and kidney function biomarkers [creatinine – urea - blood urea nitrogen (BUN)]. Liver was dissected to determine oxidative stress biomarkers [malondialdehyde (MDA) - glutathione (GSH) - superoxide dismutase (SOD)]. Also, histopathological and immunohistochemical examinations were estimated. Results: hyperlipidemic rats showed significant increments in all measured biomarkers as compared to nano-vehicle control group. SV treated rats showed significant decrease in all mentioned parameters as compared to hyperlipidemic group. Histopathological findings of hyperlipidemic rats showed fatty change in liver tissue and fat droplet deposition with zenkers necrosis in quadriceps muscle tissue section. While, Histopathological findings of SV treated rats showed vacuolar degeneration with some inflammatory cells in liver tissue and also showed fatty deposition between muscle bundles with some atrophied cells in quadriceps muscle tissue. Positive caspase-3 reactivity was noticed in liver and quadriceps muscle in hyperlipidemic and SV treated rats. Treatment with SVNPs 20, SVNPs 5, combined regimen of SV & coQNPs and combined therapy of SV & SeNPs showed significant enhancement in the measured parameters and histopathological and immunohistochemical findings. The triple combination therapy of SV& coQNPs & SeNPs caused significant enhancement in lipid profile biomarkers and marked increase in the other parameters as compared to SV treated group. Histopathological findings in rat’s liver upon administration of this triple combination showed vacuolar degeneration with inflammatory cells and also fat deposition between muscle bundles and atrophy was observed in rat’s quadriceps muscle section. Also, Positive caspase-3 reactivity was noticed in liver and quadriceps muscle of rats treated by this triple combination. Conclusion: The present results indicate that Administration of SVNPs 20 or SVNPs 5 on hyperlipidemic rats produced an anti-hyperlipidemic, anti-hyperglycemic efficacy and anti-oxidant with lower side effects and the combination therapy of SV & coQNPs and combined treatment of SV & SeNPs exhibited better therapeutic effects than treatment with simvastatin alone with hepatotoxic and myopathic side effects. Unfortunately, the concurrent administration of SV & coQNPs & SeNPs produced anti-hyperlipidemic and anti-hyperglycemic effects with higher incidence of hepatotoxicity, renotoxicity and rhabdomyolysis with regard to SV alone. Keywords: Hyperlipidemia, simvastatin, hepatotoxicity, rhabdomyolysis, nanomedicine, lipid profile, oxidative stress, myoglobin. |
| 546 ## - LANGUAGE NOTE | |
| Language note | Text in English, abstracts in English and Arabic. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| 9 (RLIN) | 4488 |
| Topical term or geographic name as entry element | Pharmacology & toxicology. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 4928 |
| Personal name | Khattab,Mahmoud M. , |
| Relator term | Supervisor |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 4929 |
| Personal name | Hamzawy, Mohamed A. , |
| Relator term | Supervisor |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 4930 |
| Personal name | Abdalsalam, Rania E. , |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Theses |
| Item part | Faculty of Pharmacy كلية الصيدلة |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection code | Permanent location | Current location | Shelving location | Date acquired | Full call number | Barcode | Date last seen | Copy number | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Default | 6october | 6october | 1208 | 2019-01-14 | 615 A P | SOULE208TH0806 | 2021-08-25 | 1 | 2019-01-14 | Theses |